Printer Friendly

Merck reports positive data from Keytruda phase three Keynote-181 oesophageal cancer trial.

M2 EQUITYBITES-November 16, 2018-Merck reports positive data from Keytruda phase three Keynote-181 oesophageal cancer trial

(C)2018 M2 COMMUNICATIONS http://www.m2.com

United States-based Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), significantly improved overall survival rate in the phase three Keynote-181 oesophageal cancer trial, it was reported yesterday.

The phase 3 Keynote-181 study evaluating the product as monotherapy in the second-line treatment of advanced or metastatic oesophageal or oesophagogastric junction carcinoma has achieved a primary endpoint of overall survival in patients whose tumours expressed PD-L1.

The product is an anti-PD-1 therapy, which works by improving the ability of the body's immune system to help detect and inhibit tumour cells. It is a humanised monoclonal antibody that prohibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, enabling to activate T lymphocytes that may affect both tumour cells and healthy cells. In the phase 3 Keynote-181 study, the patients treated with Keytruda indicated a statistically significant improvement in overall survival compared with patients treated with chemotherapy. The primary endpoint of overall survival was also evaluated in patients with squamous cell histology, in addition to the entire intention-to-treat study population.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Nov 16, 2018
Words:199
Previous Article:Graphic Packaging announces dividend of USD0.075 per share for quarter.
Next Article:Arion Bank concludes issue of SEK500m of subordinated bonds.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |